Start-up factory

KAHIMMUNE THERAPEUTICS

Reexploring the Cancer Immunopeptidome

Discovery and development of novel mRNA-based companion neoantigen therapies for the treatment of cancer

CEO : Philippe Villain-Guillot

Creation : november 2025

Headcount : 2

Location : Avignon

Market(s) : Healthcare

https://kahimmune.com/

#Immuno-Oncology #Neoantigen #mRNA

TECHNO / PRODUITS

KahinomicsTM: innovative neoantigen discovery platform leveraging groundbreaking insights into the “dark genome”.

PRODUCTS PORTFOLIO

  • KAH-001: novel candidate neoantigen therapy for the treament of colorectal cancer

APPLICATIONS

Drug discovery in oncology.

ADVANTAGES

Synergic enhancement of cancer therapies.